Evidence map›Paper›PMID 35781154›Full record

ReviewGaceta sanitaria2022

[Towards COVID-19 control through vaccination: obstacles, challenges and opportunities. SESPAS Report 2022].

Pere Godoy, Jesús Castilla, Jenaro Astray, Sofía Godoy, José Tuells, Irene Barrabeig, Ángela Domínguez

Abstract readReview
In one paragraph

Review in Gaceta sanitaria, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pere GodoyAgència de Salut Pública de Catalunya, Barcelona, España; CIBER de Epidemiología y Salud Pública (CIBERESP), España; Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, España. Electronic address: pere.godoy@gencat.cat.
Jesús CastillaCIBER de Epidemiología y Salud Pública (CIBERESP), España; Instituto de Salud Pública de Navarra-IdiSNA, Pamplona, España.
Jenaro AstrayDirección General de Salud Pública, Subdirección General de Epidemiología, Comunidad de Madrid, Madrid, España.
Sofía GodoyInstitut Català de la Salut (ICS), Lleida, España.
José TuellsDepartamento de Salud Pública, Universidad de Alicante, Alicante, España.
Irene BarrabeigAgència de Salut Pública de Catalunya, Barcelona, España; CIBER de Epidemiología y Salud Pública (CIBERESP), España.
Ángela DomínguezCIBER de Epidemiología y Salud Pública (CIBERESP), España; Departament de Medicina, Universitat de Barcelona, Barcelona, España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Spain, the vaccination program began in a context of high transmission and low availability of vaccines. The objective of this article is to review the vaccination program against COVID-19 in Europe (3/03/2022) and assess the obstacles, challenges and opportunities posed by the control of this disease. Five vaccines are currently available in Europe: two based on mRNA technology (Comirnaty® and Spikevax®); two based on a non-replicative vector (Vaxzevria® and Janssen); and another based on subunit S (Novavax®). Health authorities have developed comprehensive vaccination strategies prioritizing the prevention of hospitalizations and deaths. In January 2022, 90% of the population was exceeded with full vaccination and 95% coverage in people over 50 years of age. The new challenge is to achieve similar coverage in the rest of the age groups. Vaccination in children and adolescents has become a priority due to the educational and social implications derived from COVID-19 in this population. Communication strategies must be renewed and access barriers eliminated to achieve good coverage. In Spain, studies have been published that find a high effectiveness of vaccination. The main strategy for controlling the pandemic and recovering social activity is the vaccination, but everything indicates that very high levels of vaccination coverage will be necessary and to follow with the non-pharmaceutical measures. In a globalized world, COVID-19 control will only be achieved with a coordinated global strategy and technical and economic support for the vaccination strategy in resource-poor countries.

Indexed as

COVID-19Influenza VaccinesAdolescentChildHumansImmunization ProgramsMiddle AgedPandemicsVaccinationInfluenza VaccinesCOVID-19EpidemiologíaEpidemiologyEvaluaciónEvaluation studySARS-CoV-2VaccinesVacunas

Identifiers

PMID35781154
PMCPMC9244662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.